Bioassay for Breast Cancer Prevention

描述(由申请人提供)：本申请涉及广泛的挑战领域(01)行为，行为改变，以及预防和特定挑战主题01-CA-102，营养在癌症生物学中的作用。我们的长期目标是确定基因组稳定性在饮食预防癌症中的作用，并开发一种中间的DNA损伤生物检测方法，以测试饮食制剂的有效性。这些研究将为这一概念的原理提供证据，并通过对维生素D和基因组稳定性的研究建立生物测定。该项目从以下几个方面特别针对“预防”和“营养在癌症生物学中的作用”这一挑战：1.关注正常乳腺细胞和癌症预防。我的实验室已经广泛研究了维生素D对乳腺癌细胞的影响，目的是将维生素D受体(VDR)作为癌症治疗的靶点。不幸的是，在临床试验中，患者患有晚期癌症，以维生素D为基础的治疗效果微乎其微。许多其他营养素和营养衍生品(如维生素A、维生素E等)也有类似的结果。因此，我们开始研究维生素D对正常乳腺的影响，认为维生素D在预防癌症方面是有效的。事实上，我们发现VDR缺失的小鼠对化学和癌基因诱导的致癌表现出更高的敏感性。这项建议直接针对广泛的预防挑战领域，计划全面研究维生素D治疗如何在体外和体内对正常人类和小鼠乳腺细胞的DNA损伤反应通路产生影响。2.在体内测试膳食维生素D补充剂。维生素D的饮食需求最初是为了预防骨骼疾病软骨病而设定的。当时，维生素D在癌症预防中的作用还没有得到承认。因此，我们知道最佳骨骼生长需要多少维生素D，然而，我们不知道表达VDR的其他组织(如乳房)的最佳健康需要多少维生素D。我们方法的一项创新是，我们将饮食中的维生素D增加5倍、10倍和20倍以上的“标准啮齿动物需要量”。这是基于这样一个事实，即我们只是不知道多少才够(我们从之前对钙代谢的研究中确实知道，这些水平是无毒的)。3.建立一种检测化学预防药物对DNA损伤反应影响的中间生物测定方法。尽管基于细胞的研究已经开始证明营养物质对基因组稳定性的影响，但将体外数据扩展到更复杂的组织环境，模拟体内癌症的发展显然是一个挑战。关于监测双链断裂(DSB)造成的DNA损伤，体内研究特别困难，因为遗传毒性物质在多个组织中的随机位置诱导DSB，而正是这些断裂容易出错的修复导致整个基因组的突变。一旦癌症最终发展，对DNA的初始损伤就不再可识别。因此，我们建议在暴露于遗传毒性物质的器官培养中验证使用乳腺的生物测定(我们将使用辐射和阿霉素，但这种测定可以适用于其他感兴趣的遗传毒性物质)。这将允许准确控制暴露于乳腺内的遗传毒性物质，并监测立即损害(DSB)。此外，我们相信，利用完整组织的生物测定将更紧密地模拟与癌症预防相关的体内生物学。我们设计的一个主要优点是能够在去除腺体进行培养之前操纵小鼠的饮食，因此可以在饮食/血清营养素水平和生物检测中的有效性之间建立关联。我们这项为期两年的挑战资助的目的是通过研究补充膳食维生素D的效果来提供原则上的证据。如果得到验证，这种生物测定可能被证明是一种有用的中间方法，用于筛选优化DNA损伤反应途径的饮食制剂。当然，作为选择，人们可以使用基因敲除或转基因小鼠作为捐赠者，来探索特定的基因-营养相互作用，以调节乳腺中的DNA损伤反应通路。4.启动预防基因组数据库。我们方法的另一个吸引人的方面是，人们可以从同一动物身上收集多个腺体，并同时将生物测定中化学预防药物的有效性与基因组或蛋白质组图谱进行比较。与细胞培养研究不同，生物测定将允许在所有乳腺细胞群体(上皮细胞、间质细胞、免疫细胞、内皮细胞等)的背景下分析基因表达的变化。从长远来看，将建立一个在这一生物检测中有效的预防性药物诱导的基因组图谱数据库。最终，这个数据库有望产生一套与维持基因组稳定的癌症预防药物相关的通用生物标记物。 公共卫生风险：人们持续暴露在可导致基因突变和增加癌症发展风险的环境因素中。幸运的是，健康的组织可以修复这些突变中的大部分，但随着时间的推移，一些细胞确实最终积累了足够的损害，使它们变成癌症。基于这一与年龄相关的损伤积累的范例，饮食因素可能通过最大化组织修复过程来延缓癌症的发展。在这个项目中，我们将开发研究乳腺损伤和修复过程的方法，并将进行初步实验，以测试维生素D是否通过增强细胞保护反应来预防乳腺癌。

DESCRIPTION (provided by applicant): This application addresses broad Challenge Area (01) Behavior, Behavioral Change, and Prevention and specific Challenge Topic 01-CA-102, The Role of Nutrition in Cancer Biology. Our long term goals are to characterize the role of genomic stability in dietary prevention of cancer and to develop an intermediate bioassay of DNA damage for testing efficacy of dietary agents. These studies will provide proof of principle of this concept and establish the bioassay through study of vitamin D and genomic stability. This project specifically targets the Challenges "Prevention" and "Role of Nutrition in Cancer Biology" in the following ways: 1. Focus on normal mammary cells and cancer prevention. My lab has extensively studied the effects of vitamin D on breast cancer cells with the idea of targeting the vitamin D receptor (VDR) for cancer therapy. Unfortunately, in clinical trials, patients had late stage cancer and exhibited minimal improvement with vitamin D based therapies. Similar results have been reported with many other nutrients and nutrient derivatives (ie, vitamin A, vitamin E, etc). Thus, we began studying the effects of vitamin D on normal mammary gland with the idea that vitamin D would be effective in prevention of cancer. Indeed, we showed that VDR null mice display enhanced sensitivity to chemical and oncogene induced carcinogenesis. This proposal directly targets the Broad Challenge Area of Prevention with the plan to comprehensively study how vitamin D treatment impacts on DNA damage response pathways in normal human and mouse mammary cells in vitro and in vivo. 2. Testing dietary vitamin D supplementation in vivo. Dietary requirements for vitamin D were originally set for prevention of the bone disease rickets. At the time, a role for vitamin D in cancer prevention was not recognized. Thus, we know how much vitamin D is required for optimal bone growth, however, we do not know how much vitamin D is required for optimal health of other tissues that express the VDR such as the breast. One innovation of our approach is that we will increase dietary vitamin D 5, 10 and 20 fold above the "standard rodent requirement". This is based on the fact that we just don't know how much is enough (we do know from our previous studies on calcium metabolism that these levels are not toxic). 3. Development of an intermediate bioassay for testing effects of chemopreventive agents on the DNA damage response. Although cell based studies have begun to demonstrate effects of nutrients on genomic stability, extension of in vitro data to a more complex tissue environment that mimics cancer development in vivo is obviously a challenge. With respect to monitoring DNA damage resulting from double strand breaks (DSB), in vivo studies are especially difficult because genotoxic agents induce DSBs at random sites in multiple tissues, and it is the error-prone repair of these breaks that cause mutations throughout the genome. The initial damage to the DNA is no longer identifiable once cancer eventually develops. We therefore propose to validate a bioassay using mammary gland in organ culture exposed to genotoxic agents (we will use radiation and doxorubicin, but this assay could be adapted for other genotoxic agents of interest). This will allow exact control over exposure to genotoxic agents within the mammary gland, and monitoring of the immediate damage (DSBs). In addition, we believe that a bioassay that utilizes intact tissue will more closely model the in vivo biology relevant to cancer prevention. A major strength of our design will be the ability to manipulate the diets of mice prior to removal of the glands for culture and thus correlation can be made between dietary/serum levels of nutrients and effectiveness in the bioassay. Our aim for this two year challenge grant is to provide proof of principle by studying the effects of supplemental dietary vitamin D with this approach. If validated, this bioassay could prove useful as an intermediate approach for screening dietary agents that optimize DNA damage response pathways. Alternatively, of course, one could use knockout or transgenic mice as donors to probe specific gene-nutrient interactions in modulation of DNA damage response pathways in the mammary gland. 4. Initiation of a prevention genomic database. Another attractive aspect of our approach is that one can collect multiple glands from the same animal and simultaneously compare effectiveness of chemopreventive agents in the bioassay with genomic or proteomic profiles. In contrast to cell culture studies, the bioassay will allow profiling of gene expression changes in the context of all mammary cell populations (epithelial, stromal, immune, endothelial, etc). In the long term, a database of genomic profiles induced by preventive agents effective in this bioassay will be developed. Ultimately, this database is expected to generate a common set of biomarkers associated with cancer preventive agents that maintain genomic stability. PUBLIC HEALTH RELEVENCE: People are continuously exposed to environmental agents that can cause genetic mutations and increase the risk of cancer development. Fortunately, healthy tissues can repair the majority of these mutations, some cells do eventually accumulate enough damage over time that they become cancerous. Based on this paradigm of age-related accumulation of damage, it stands to reason that dietary factors might delay cancer development by maximizing tissue repair processes. In this project we will develop methods to study damage and repair processes in mammary gland, and will perform initial experiments to test whether vitamin D acts to prevent breast cancer via enhancement of cellular protective responses.